-+ 0.00%
-+ 0.00%
-+ 0.00%

BioInvent seeks shareholder approval for SEK 430 million rights issue

PUBT·10/28/2026 17:21:11
Listen to the news
BioInvent seeks shareholder approval for SEK 430 million rights issue
  • BioInvent seeks shareholder approval for an approximately SEK 430 million rights issue at an extraordinary general meeting scheduled for December 1, 2026.
  • Proceeds will fund priority clinical programs, principally solid tumor treatments BI-1808 and BI-1206.
  • Subscription commitments and guarantee undertakings cover approximately SEK 350 million, or 81%, of the rights issue.
  • Van Herk Investments proposes electing Dharminder Chahal to the board at the meeting.
  • Major shareholders and shareholding directors and management have committed or indicated their intention to vote for the rights issue and necessary resolutions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioInvent International AB published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.